Can Weed Help With BPD? What the Science Says

No clinical trial has tested whether cannabis treats borderline personality disorder, so there is no direct evidence that weed “helps” with BPD in any medical sense. What does exist is a growing body of research on the endocannabinoid system’s role in the emotional instability that defines BPD, along with a separate and sobering body of evidence showing that cannabis use in this population is linked to worse outcomes on several fronts. The gap between theoretical promise and real-world risk is wide, and understanding both sides matters if you or someone you know is navigating BPD and considering cannabis.

Why People With BPD Use Cannabis So Often

Cannabis is one of the most commonly used substances among people with BPD. A large population-based twin study found a strong association between borderline personality features and both cannabis use and cannabis use disorder, even after adjusting for age and sex.¹ That association is not just about recreational enjoyment. Research into why people with BPD reach for different substances consistently finds that coping motives dominate. In a study examining substance use motives across alcohol, cannabis, and prescription opioids, BPD features were most strongly linked to using cannabis to cope with negative emotions, and this held for both men and women.²

This pattern makes intuitive sense. BPD is defined by intense emotional swings, chronic feelings of emptiness, and difficulty tolerating distress. Cannabis can produce rapid short-term relief from anxiety and emotional pain. The problem is that using a substance primarily to manage difficult emotions, rather than for social or enhancement reasons, is one of the strongest predictors of developing a substance use disorder. People with BPD are not just more likely to use cannabis; they are more likely to develop problematic patterns of use.

The Endocannabinoid System and BPD

The reason researchers are even interested in the cannabis-BPD connection goes deeper than self-medication patterns. Your body produces its own cannabinoid-like molecules, and the system that manages them appears to be altered in people with BPD in ways that track closely with the disorder’s core symptoms.

A 2020 review paper focused on two brain regions that are consistently abnormal in BPD: the corticolimbic system, which handles emotion regulation, and the hypothalamus, which governs stress responses. Both regions have dense concentrations of cannabinoid receptors.³ This overlap between where BPD causes trouble in the brain and where the endocannabinoid system is most active has made it a natural research target.

A study measuring blood levels of the body’s own cannabinoids found that female BPD patients had higher levels of anandamide (one of the two main endocannabinoids) compared to healthy controls, with a similar trend for the other main endocannabinoid, 2-AG.⁴ The researchers interpreted this as the body’s attempt to compensate for something going wrong in the system. A separate brain-imaging study found elevated levels of the enzyme FAAH in the prefrontal cortex of people with BPD. FAAH breaks down anandamide, so having more of it means your natural cannabinoid signaling gets degraded faster. The researchers linked this to poorer regulation of emotion and aggression.⁵

Taken together, these findings suggest that BPD involves a kind of endocannabinoid deficit in key brain circuits. The body tries to produce more cannabinoids, but the enzymes that break them down are also overactive, so the compensation falls short. This creates a plausible biological rationale for why cannabinoid-based treatments might someday help. But “plausible biological rationale” is very far from “works in patients.”

What the Research Actually Finds About Cannabis Use and BPD Symptoms

Here is where the picture gets uncomfortable for people hoping cannabis is a treatment. Nearly every study that looks at real-world cannabis use in people with BPD finds associations with worse, not better, outcomes.

A systematic review and meta-analysis of studies on cannabis use and self-injurious behavior found that cannabis use was significantly associated with self-harm both at a single point in time and when researchers followed people over time. The longitudinal link was especially strong. The same review noted that the risk was amplified by the presence of mental disorders, emotional dysregulation, and impulsive traits, which are hallmarks of BPD.⁶ Self-harm is already one of the most dangerous features of BPD, and anything that increases its likelihood warrants serious caution.

Cannabis use has also been linked to suicidal ideation in a study of young adults that controlled for other substance use and demographic factors. Even after accounting for alcohol, tobacco, and tranquilizer use, cannabis remained a significant independent predictor of suicidal thoughts.⁷ This does not prove cannabis caused the suicidal thinking. But among people already at elevated risk for suicide, the association is hard to ignore.

Cannabis and Psychosis Vulnerability in BPD

One of the more striking recent findings involves the interaction between cannabis use and psychosis-like experiences in people with BPD features. A 2025 study found that cannabis use moderated the relationship between psychosis-like experiences and BPD symptom severity. The interaction was complex: among people who reported few psychosis-like experiences, heavier cannabis use was actually associated with the lowest BPD symptom scores. But among people with many psychosis-like experiences, heavier cannabis use was associated with the highest BPD symptom scores.⁸

This crossover pattern means cannabis does not do the same thing to everyone with BPD. If you happen to have minimal psychosis vulnerability, cannabis might seem helpful or at least neutral. But if you are already prone to dissociation, paranoid thinking, or brief psychotic episodes (all of which occur in BPD), cannabis may amplify exactly the symptoms you are trying to escape. The trouble is that many people with BPD do experience these phenomena, and most people do not have a reliable way to gauge their own psychosis vulnerability before lighting up.

Why Cannabis Withdrawal Is Especially Difficult With BPD

Even setting aside the question of whether cannabis helps or hurts BPD symptoms, the practical reality of dependence and withdrawal creates a distinct problem for this population. Cannabis withdrawal is real and clinically recognized, and its most common symptoms are anxiety, irritability, anger or aggression, disturbed sleep, and depressed mood.⁹

Read that list again and compare it to what BPD already involves: intense anxiety, rapid mood swings, anger, insomnia, and chronic depression. Cannabis withdrawal does not just add new symptoms on top of BPD. It intensifies the very symptoms that drove the person to use cannabis in the first place. This creates a vicious cycle: you use cannabis to manage emotional instability, develop tolerance, and when you try to cut back, you experience a surge of the exact distress you were trying to escape. The result is that stopping feels unbearable, which reinforces continued use and makes treatment harder.

For clinicians working with BPD patients, this overlap between withdrawal symptoms and the underlying disorder complicates treatment planning. It can be genuinely difficult to tell whether a patient’s worsening mood is a flare of BPD, a withdrawal effect, or both. Gradual tapering, combined with therapy that builds distress tolerance skills (like dialectical behavior therapy), is generally more realistic than abrupt cessation for heavy users with BPD.

CBD Versus THC and What Researchers Are Exploring

When researchers talk about the therapeutic potential of the endocannabinoid system for BPD, they are emphatically not talking about the high-THC cannabis products you buy at a dispensary. The review paper that generated the most interest in this area concluded that while the evidence does not yet support recommending cannabinoid treatment for BPD, if such a treatment were developed, the appropriate approach would involve a high ratio of CBD to a low amount of THC. The same paper called for randomized controlled trials to test this, and as of now, no such trial has been published.³

This distinction between CBD and THC is critical. CBD does not produce the intoxicating effects associated with marijuana, and it interacts with the endocannabinoid system differently. Some early research in other conditions, such as anxiety disorders, suggests CBD may have calming properties without the cognitive impairment and psychosis risk that THC carries. THC, on the other hand, is the component most associated with dependence, psychosis-like experiences, and the short-term emotional numbing that people with BPD are chasing when they use cannabis to cope.

If you have BPD and you hear that “the endocannabinoid system is involved in the disorder,” it would be easy to assume that smoking weed is doing something therapeutically meaningful. What the research actually suggests is that your endocannabinoid system may need fine-tuned correction at specific receptor sites, not the broad, blunt activation that comes from inhaling THC-rich smoke. The gap between a targeted pharmaceutical intervention and a recreational drug is enormous, even when both technically involve cannabinoids.

The Self-Medication Trap

People with BPD often describe cannabis as one of the few things that “takes the edge off.” That subjective experience is real and should not be dismissed. The emotional pain of BPD is severe, and when someone finds something that provides even temporary relief, telling them to stop without offering a viable alternative is neither compassionate nor effective.

But the pattern that research reveals is that cannabis use in BPD tends to function as a coping-driven behavior rather than a therapeutic one.² Coping-motivated substance use provides short-term emotional escape but does not build the skills or neural pathways needed for long-term emotional regulation. Over time, it tends to crowd out the very strategies that do produce lasting improvement. Dialectical behavior therapy, the treatment with the strongest evidence base for BPD, works precisely by building tolerance for intense emotions rather than avoiding them. Cannabis use that numbs distress can undermine that process.

There is also a subtler problem. Because BPD involves unstable self-image and difficulty identifying one’s own emotions, the blunting effect of THC can make it harder to access and process the emotional material that therapy needs to work on. Therapists who treat BPD sometimes report that patients who are heavy cannabis users have a harder time engaging with emotion-focused work, though this observation has not been formally studied.

What About Low-Dose or Occasional Use

Most of the alarming associations in the literature involve regular or heavy cannabis use. A natural follow-up question is whether occasional, low-dose use carries the same risks. Honestly, the research does not offer a clear answer. Almost all studies on cannabis and BPD measure frequency or presence of use rather than dose. The crossover finding from the psychosis vulnerability study hints that the picture varies significantly depending on individual risk factors, but it does not give dose-specific guidance.⁸

What is known more broadly is that people with BPD have difficulty with moderation in general. Impulsivity is a core feature of the disorder, and occasional use frequently escalates to regular use, which frequently escalates to problematic use. The intention to “just use it sometimes” runs into the reality that BPD makes it hard to stop doing something that feels good in the moment, even when you know it is causing problems. This is not a moral failing; it is a neurobiological feature of the disorder itself.

FAAH Inhibitors and Other Pharmaceutical Approaches

The most scientifically interesting angle in this story is not about cannabis the plant at all. It is about drugs that could boost your body’s own endocannabinoid signaling without the drawbacks of THC. The finding that people with BPD have elevated FAAH, the enzyme that breaks down anandamide in the prefrontal cortex, suggests a specific drug target.⁵ If a drug could safely inhibit FAAH, it would allow anandamide to stick around longer in the circuits that regulate emotion, potentially addressing the endocannabinoid deficit without flooding the whole brain with an external cannabinoid.

FAAH inhibitors have been studied in other psychiatric conditions, with mixed results. One early clinical trial of a FAAH inhibitor in a different company’s program had to be stopped due to safety concerns, which slowed the field. But the concept remains active in psychiatric drug development. For BPD specifically, no FAAH inhibitor trial has been conducted, and the endocannabinoid findings in BPD patients are still relatively new. The 2023 study measuring plasma endocannabinoid levels in BPD patients involved just 49 patients and 32 controls, which is enough to generate a signal but not enough to build a treatment on.⁴

This is where the science stands: researchers have identified a plausible biological system, found measurable differences in that system in people with BPD, proposed a reasonable therapeutic direction (high CBD-to-THC ratios or FAAH inhibition), and called for clinical trials. Those trials have not happened yet. Anyone claiming that cannabis is a treatment for BPD is running ahead of what the evidence supports. And anyone claiming it is categorically harmless for people with BPD is ignoring the data on self-harm, suicidality, psychosis interactions, and withdrawal-symptom overlap that should give any clinician pause.

1
PubMed Central. Associations between personality disorders and cannabis use and cannabis use disorder: a population-based twin study
2
PubMed. Borderline personality disorder features and drinking, cannabis, and prescription opioid motives: Differential associations across substance and sex
3
PubMed Central. Targeting the Endocannabinoid System in Borderline Personality Disorder: Corticolimbic and Hypothalamic Perspectives
4
PubMed Central. Plasma Endocannabinoid Levels in Patients with Borderline Personality Disorder and Healthy Controls
5
Neuropsychopharmacology. Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [11C]CURB positron emission tomography study
6
PubMed. Cannabinoid use and self-injurious behaviours: A systematic review and meta-analysis
7
Revista Colombiana de Psiquiatría. Association Between Suicidal Behaviour and Cannabis and Tranquilizer use, Depression, Aggression and Other Borderline Personality Traits Among Students in Sincelejo, Colombia
8
PubMed Central. Cannabis Use Interacts With Psychosis Vulnerability in Borderline Personality Disorder
9
Wiley Online Library. Clinical management of cannabis withdrawal